eClinical Tech News

Cosciens Biopharma has voluntarily delisted from Nasdaq, maintained its Toronto Stock Exchange listing, and is seeking quotation on the...

Opus Genetics reported a pivotal quarter for its inherited retinal disease portfolio, highlighting positive Phase 1/2 data for its...

Legend Biotech reported third-quarter 2025 results anchored by accelerating commercial momentum for Carvykti, including estimated net trade sales of...

Humacyte reported third-quarter 2025 revenue of $753,000, primarily driven by a ramp in U.S. sales of SymVESS, its FDA-approved...

Metagenomi has restructured around a single, near-term bet: in vivo genome editing for hemophilia A. The company reported new...

CRISPR Therapeutics reported a mixed but mobilizing third quarter: the first CRISPR-based therapy continues to scale globally. At the...

Voyager Therapeutics used its third-quarter update to reset its narrative around neurodegeneration and blood–brain barrier access. The company advanced...

Cabaletta Bio moved its CD19-directed CAR-T program, rese-cel, a step closer to registration, outlining plans to initiate a 14-patient,...

Wave Life Sciences reported third-quarter 2025 results, alongside two meaningful clinical updates that reposition its RNA toolkit squarely in...

Recordati reported a strong nine-month performance for 2025, with consolidated revenue up 12.2% to €1.96 billion, EBITDA up 11.8%...